Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children
2 other identifiers
interventional
14
1 country
1
Brief Summary
Urinary tract infection (UTI) is a common problem in childhood associated with vesico-renal reflux (VRR) in 25-40% of children. A persistent VRR and repeated pyelonephritis may predispose to renal scarring and chronic renal failure with an end-stage renal failure in up to 3% of children.Defining a standard behaviour facing VRR in children is not easy because of the lack of reliable evidence. Numbers of studies compare prospectively or retrospectively, medical, endoscopical and surgical treatment.Surgical techniques are effective but invasive and not free of complication. Medical treatment is submissive to a good observance. The introduction of endoscopic techniques permits to prevent UTI and new renal failure by VRR elimination. Since the beginning of the endoscopic treatment, several bulking agents have been proposed. The ideal agent should be easy to inject, stable in time and should be safe. Of course it should be at least as efficient as actual bulking agent. The use of Teflon was the first wave of success of endoscopic treatment. But sudden passion of Teflon has been darkened by the notion of migration. Since, others substances have been proposed, autologous or exogenous, resorbable or not. But none was ideal and no solutions were found facing problem of biocompatibility or long-term stability.Using adipose tissue as a bulking agent is ancient in plastic surgery and indications had known a leap forward in the last century with Coleman who introduced a new technique called "lipostructure". This technique has known a growing interest in the restoration of all volume defects in plastic surgery because of the stability of the graft. We propose to apply this technique to VRR management in children in order to combine innocuousness and efficiency.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Jan 2007
Longer than P75 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 21, 2006
CompletedFirst Posted
Study publicly available on registry
August 22, 2006
CompletedStudy Start
First participant enrolled
January 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2021
CompletedFebruary 25, 2009
February 1, 2009
13.6 years
August 21, 2006
February 24, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Realization of an urethrocystography
at 3 months and 1 year
Secondary Outcomes (1)
Clinical or biological diagnosis of a pyelonephritis during the follow up (10 years)
Day 1; Month 1; Month 3 ; Year 1; Year 5 and Year 10
Interventions
Autologous Adipocytes Graft (lipostructure)
Eligibility Criteria
You may qualify if:
- sexe : male and female
- age : 3 to 15 years
- written consent
- Vesico-renal reflux staged I to III revealed by a pyelonephritis ; after failure of medical treatment or parent refusal of medical treatment or initial renal failure.
You may not qualify if:
- Before 3 years or older than 15 years
- insulino-dépendant diabet
- neurologic bladder
- abnormalities of the urinary tract
- kidney transplantation
- past history of bladder surgery
- anorexia (BMI \<12)
- Vesico-renal reflux staged IV or V
- Active urinary tract infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service de Chirurgie Infantile, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg
Strasbourg, 67098, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
François BECMEUR, MD
Hôpitaux Universitaires de Strasbourg
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 21, 2006
First Posted
August 22, 2006
Study Start
January 1, 2007
Primary Completion
August 1, 2020
Study Completion
February 1, 2021
Last Updated
February 25, 2009
Record last verified: 2009-02